Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG

Cenix logo

Dresden, Germany, May 5, 2014 / B3C newswire / – Cenix BioScience GmbH (Cenix), a leading preclinical contract research provider and technology developer specialized in RNAi-based genomics and high content screening-driven pharmacology, today announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).

Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.

Financial terms were not disclosed.

About Cenix BioScience
With operations in Germany and the U.S., Cenix BioScience conducts contract research and develops new reagent technologies focused on a wide array of preclinical cell-based and in vivo applications including RNAi-based gene silencing, miRNA modulation, compound testing, advanced genomics analyses and high content screening to accelerate drug discovery and development. Now in its 15th year, Cenix has established unrivaled scientific and commercial track records in this field, successfully advancing therapeutic programs for numerous industry and academic partners in a broad range of disease fields. This success, illustrated by a high rate of repeat business from top clients, is driven by the consistent application of industrial best practices through highly customized, multi-staged projects carefully designed for maximal strategic value and accountability, with minimized risk and full data transparency. More information: www.cenix.com

Dr. Christoph Sachse
Director Cell-based Services
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.cenix.com

Cenix and the Cenix BioScience logo are registered trademarks owned by Cenix BioScience GmbH.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.